or search for allinseo plug in" Body Health Advisor » Blog Archive » Advice on Health and Body Matters

Diabetics - If you are taking Levemir, take note

I saw this article, first published in June 13 2009 and felt it important to share….

FDA Issues Public Health Advisory Regarding Levemir Insulin

The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market. Three lots or a total of 129,000 vials of this product were stolen in all. These stolen insulin vials may not have been stored and handled properly and may be dangerous for patients to use.

The FDA has received one report of a patient who suffered an adverse event due to poor control of glucose levels after using a vial from one of these three lots.

The agency is advising patients who use Levemir insulin to:

1. Check your personal supply of insulin to determine if you have Levemir insulin from one of the following lots: XZF0036, XZF0037, and XZF0038. Patients can locate the lot number on the side of the box of insulin and also on the side of the vial.

2. Do not use your Levemir insulin if it is from one of these lots. Replace it with a vial of Levemir insulin from another lot. If you must switch to another brand of insulin for any reason, first contact your healthcare provider as another insulin product may require adjustments in dosing.

3. Always visually inspect your insulin before using it. Levemir is a clear and colorless solution.

4. Contact the Novo Nordisk Customer Care Center at 800-727-6500 for what to do with vials from these lots or if you have any other questions.

For more information:
Novo Nordisk news release

Technorati Tags:

Tags: , ,

Leave a Reply

  • A possible replacement of Rosiglitazone and Pioglitazone for Type II Diabetes?
    Findings from the Phase II SYNCHRONY study show that aleglitazar, a treatment for Type 2 diabetes, could be safe and effective and thus will be entered into Phase III trials. The data, already published online and forthcoming in The Lancet, were presented at the recent American Diabetes Association meeting in New Orleans, La. Aleglitazar is in [...]
  • New Hope for Type II Diabetics
    GlaxoSmithKline in February announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety, and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria® (albiglutide) in men and women with type 2 diabetes. The Phase III program will include more than 4,000 patients […]
  • New Studies on Weight Loss Drug - promising results
    I know that many chronic obese people rely on Weight loss drugs to control their weight. No doubt despite the side effects, some people have really tried everything to natuarally lose weight, but to no avail. With a doctor’s advice, they resort to medication. These naturally come with side effects, and sometimes are not even [...]
  • Warning about Venom HYPERDRIVE 3.0 supplements
    FDA Warns Consumers Against Dietary Supplement Containing Undeclared Drug Product poses safety risk The U.S. Food and Drug Administration is warning consumers not to take Venom HYPERDRIVE 3.0, a product sold as a dietary supplement and containing sibutramine. Sibutramine, a controlled substance with risks for abuse or addiction, is a potent drug [...]
Pages
H1N1 Fraudulent Products update







Tai Chi WeightLoss